Monoclonal antibodies (mAbs) that regulate the immune response are now being clinically evaluated as anticancer agents. This Review discusses their progress to date and the possibilities for combining these antibodies with other cancer treatments.
- Ignacio Melero
- Sandra Hervas-Stubbs
- Lieping Chen